Measuring waistline, blood pressure, cholesterol, blood fats, and blood sugar during doctor visits can detect heart disease and diabetes earlier, according to a Clinical Practice Guideline issued today by the Endocrine Society.
The guideline, titled “Primary Prevention of CVD and T2DM in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline,” was published online and will appear in the September 2019 print issue of The Journal of Clinical Endocrinology & Metabolism (JCEM), a publication of the Endocrine Society.
The five risk factors for heart disease and diabetes are – large amount of abdominal body fat, low HDL (“good”) cholesterol, high levels of fat in the blood known as triglycerides, high blood pressure, and high blood sugar. Patients with at least three of these factors are at metabolic risk (higher risk for heart disease and diabetes). The guideline recommends screening patients with three or more risk factors regularly and screening patients with one or two risk factors every three years. This is in addition to assessing risk factors for cardiovascular disease like “bad” cholesterol, smoking and family history.
“Doctors haven’t been doing enough to measure waist circumference, but it’s essential to identifying patients at metabolic risk earlier and preventing more cases of heart disease and diabetes.”
The original Endocrine Society guideline on this topic was published in 2008. This revision takes a fresh look at metabolic risk and presents recommendations which reflect more recent trial data on blood pressure and lipids. The guideline prioritizes lifestyle and behavioral interventions and discusses new medical treatment options. The guideline is targeted towards adults aged 40 to 75 but can be used to guide patients outside of this age range as well.
“Doctors haven’t been doing enough to measure waist circumference, but it’s essential to identifying patients at metabolic risk earlier and preventing more cases of heart disease and diabetes,” says James L. Rosenzweig, MD, of Hebrew Rehabilitation Hospital in Boston, Mass. Rosenzweig chaired the writing committee that developed the guideline. “We emphasize the importance of lifestyle, dietary and behavioral changes as the first line treatment. However, treatment with medication is appropriate if goals are not met with lifestyle changes alone.”
Recommendations from the guideline include:
- Measuring waist circumference as a routine part of the clinical examination.
- Checking blood pressure annually, and, if elevated, at each subsequent visit.
- Prioritizing lifestyle modification as the first-line therapy.
- Aiming to lose five percent or more of initial body weight over the first year for individuals at metabolic risk with excess weight.
- Undergoing a 10-year global risk assessment for either coronary heart disease or atherosclerotic cardiovascular disease to guide the use of medical or pharmacological therapy.
- Prescribing lifestyle modification before drug therapy in patients with prediabetes to reduce blood sugar levels.
Other members of the Endocrine Society writing committee that developed this guideline include: George L. Bakris of University of Chicago Medicine in Chicago, Ill.; Lars F. Berglund of University of California Davis in Sacramento, Calif.; Marie-France Hivert and Edward S. Horton of Harvard Medical School in Boston, Mass.; Rita R. Kalyani of Johns Hopkins University School of Medicine in Baltimore, Md.; M. Hassan Murad of Mayo Clinic Knowledge and Evaluation Research Unit in Rochester, Minn.; and Bruno L. Vergès of Centre Hospitalier Universitaire Dijon Bourgogne in Dijon, France.
“We emphasize the importance of lifestyle, dietary and behavioral changes as the first line treatment. However, treatment with medication is appropriate if goals are not met with lifestyle changes alone.”
The Society established its Clinical Practice Guideline Program to provide endocrinologists and other clinicians with evidence-based recommendations in the diagnosis, treatment, and management of endocrine-related conditions. Each guideline is developed by a writing committee of topic-related experts in the field. Writing committees rely on evidence-based reviews of the literature in the development of guideline recommendations. The Endocrine Society does not solicit or accept corporate support for its guidelines. All Clinical Practice Guidelines are supported entirely by Society funds.
This Clinical Practice Guideline was co-sponsored by American Diabetes Association and the European Society of Endocrinology.